Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR PathwayMargaret Kasner, Alexander E. Perl, Selina M. Luger et al.|Blood|2012Cited by 3